Gastrointestinal Cancers Symposium - ASCO GI 2021

congress program
Location : Online
Country : United States
Language : ENG
Start :
End :
https://meetings.asco.org/gi/program-day
Specialities : Oncology
Bemarituzumab + mFOLFOX6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma

- Date : 2021-01-17
- 0
0
alloSHRINK: Phase I first-in-human study evaluating CYAD-101, an allogeneic CAR-T in mCRC

- Date : 2021-01-17
- 0
0
Real-world outcomes of patients with intrahepatic CCA treated with trans-arterial radioembolization

- Date : 2021-01-17
- 0
0
Outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in HCC

- Date : 2021-01-17
- 0
0
Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies

- Date : 2021-01-17
- 0
0
Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

- Date : 2021-01-17
- 0
0
CRT-induced molecular alterations and associated outcomes in patients with rectal cancer

- Date : 2021-01-17
- 0
0
Computerized food frequency questionnaire to assess dietary patterns in advanced GI cancers

- Date : 2021-01-17
- 0
0
RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

- Date : 2021-01-17
- 0
0
MSI in patients with stage III colon cancer receiving 5-FU with or without oxaliplatin

- Date : 2021-01-17
- 0
0
Disparities in access to screening and variation of targets in different groups

- Date : 2021-01-17
- 0
0
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

- Date : 2021-01-17
- 0
0
DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

- Date : 2021-01-17
- 0
0
AI-based online search tool to increase patients access to GI clinical trials

- Date : 2021-01-17
- 0
0
Genomic pathway of gut microbiome predicts efficacy of nivolumab in advanced GC

- Date : 2021-01-17
- 0
0
Prognostic value of body weight loss in previously treated metastatic gastric cancer

- Date : 2021-01-17
- 0
0
KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC

- Date : 2021-01-17
- 0
0